Only 60 spots left

~60 spots leftby Feb 2027

PF-07799933 for Advanced Cancers

Recruiting in Palo Alto (17 mi)

+44 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Pfizer

Must not be taking: Systemic anti-cancer

Disqualifiers: Brain metastasis, Retinal vein occlusion, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a new medicine, PF-07799933, for people with advanced solid tumors that have a specific gene issue and haven't responded to other treatments. Participants will take PF-07799933 as a tablet regularly, and some may also take binimetinib or receive cetuximab shots. The goal is to see if these medicines are safe and effective.

Will I have to stop taking my current medications?

The trial requires that you stop any ongoing systemic anti-cancer therapy or small molecule therapeutics before starting the study treatment.

Research Team

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Eligibility Criteria

This trial is for people with advanced solid tumors, including brain tumors, who have a specific abnormal BRAF gene and whose cancer has progressed after treatment. Participants must have tried certain therapies if they have melanoma or colorectal cancer. Those with large brain metastases or certain eye or muscle disorders cannot join.

Inclusion Criteria

I have an advanced cancer that has spread, including to the brain.

My condition worsened after my last treatment and there are no good alternative treatments.

I have melanoma or colorectal cancer and have received certain approved treatments.

See 1 more

Exclusion Criteria

I do not have a history of retinal vein occlusion or muscle disorders with high CK levels.

I am not on any cancer drugs or small molecule treatments as the study starts.

I have a brain tumor larger than 4 cm.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive PF-07799933 as a single agent or in combination with binimetinib or cetuximab, depending on the type of solid tumor

2 years

Regular visits at the study clinic

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

Binimetinib (Other)
Cetuximab (Monoclonal Antibodies)
PF-07799933 (Other)

Trial OverviewThe study tests PF-07799933 alone and combined with binimetinib for melanoma/other solid tumors, or cetuximab for colorectal cancer. PF-07799933 is an oral tablet; binimetinib is also a tablet; cetuximab is an IV shot given in the clinic.

Participant Groups

4Treatment groups

Experimental Treatment

Group I: Monotherapy dose escalation (Part 1)Experimental Treatment1 Intervention

Participants will receive PF-07799933

Group II: Dose expansion (Part 3) - Tumor and mutation specific Cohort 2Experimental Treatment2 Interventions

Participants will receive PF-07799933

Group III: Dose expansion (Part 3) - Tumor and mutation specific Cohort 1Experimental Treatment1 Intervention

Participants will receive PF-07799933

Group IV: Combination dose escalation (Part 2)Experimental Treatment3 Interventions

Participants will receive PF-07799933 in combination with binimetinib or cetuximab